
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics is expected to see significant growth in the coming years, with their ZEVASKYN gene therapy for RDEB projected to generate over $97M in revenue by 2027. Despite concerns about manufacturing bottlenecks and engraftment failures, the company is expanding their QTC network and showing steady adoption of ZEVASKYN. With a risk-adjusted net present value of $1B and a total firm value of $1.15B, the stock has potential for strong long-term growth, although there are risks such as slower uptake and potential dilution.
Bears say
Abeona Therapeutics is facing logistical hurdles with its limited experience in the process and product of gene and cell therapy, leading to production and scheduling delays and variability. Despite patient and clinician enthusiasm for pz-cel's potential, the company's limited commercial success with its approved product ZEVASKYN and potential competition from Vyjuvek position it as a complementary therapy option. While its AAV-based gene therapy programs provide further upside potential, current challenges and limited commercial success suggest a negative outlook for Abeona Therapeutics.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares